Dossier
patent cliffs
Coverage of patent cliffs in the Nexus archive.
- Patent cliffs aren’t the only driver of the biotech M&A boom
The biotech M&A boom is being driven by factors beyond patent cliffs, with many deals this year targeting early-stage assets.
- ‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Biotech mergers and acquisitions in 2026 are experiencing a strong start, driven by patent cliffs, rising public market confidence, and pharmaceutical companies seeking to enhance their drug pipelines.